Table 2.
In-Hospital Management of Patients with COVID-19 in the Well-Controlled or Poorly Controlled BG Group
| Management | Total (N = 810) | Well Controlled (n = 282) | Poorly Controlled (n = 528) | p Valueb |
|---|---|---|---|---|
| Traditional Chinese medicine (%) | 650 (80.3%) | 235 (83.3%) | 415 (78.6%) | 0.129 |
| Antiviral drug, n (%) | 553 (68.3%) | 177 (62.8%) | 376 (71.2%) | 0.017 |
| Antibiotics drug, n (%) | 501 (61.9%) | 150 (53.2%) | 351 (66.5%) | <0.001 |
| Systemic corticosteroids, n (%) | 241 (29.8%) | 57 (20.2%) | 184 (34.9%) | <0.001 |
| Immunoglobin, n (%) | 183 (22.6%) | 43 (15.3%) | 140 (26.5%) | <0.001 |
| Anti-hypertensive drug, n (%) | 380 (46.9%) | 128 (45.4%) | 252 (47.7%) | 0.575 |
| Lipid-lowering drug, n (%) | 126 (15.6%) | 40 (14.2%) | 86 (16.3%) | 0.493 |
| Vasoactive drug, n (%) | 54 (6.7%) | 7 (2.5%) | 47 (8.9%) | 0.001 |
| Antifungal medications, n (%) | 16 (2.0%) | 1 (0.4%) | 15 (2.8%) | 0.031 |
| Metformin, n (%) | 278 (34.3%) | 76 (27.0%) | 202 (38.3%) | 0.002 |
| Sulfonylurea, n (%) | 106 (13.1%) | 22 (7.8%) | 84 (15.9%) | 0.002 |
| DPP-4 inhibitor, n (%) | 55 (6.8%) | 11 (3.9%) | 44 (8.3%) | 0.025 |
| Insulin, n (%) | 328 (40.5%) | 40 (14.2%) | 288 (54.6%) | <0.001 |
| Alpha-glucosidase inhibitor, n (%) | 337 (41.6%) | 90 (31.9%) | 247 (46.8%) | <0.001 |
| Trizaolidinedione, n (%) | 9 (1.1%) | 2 (0.7%) | 7 (1.3%) | 0.508 |
| Meglitide | 35 (4.3%) | 7 (2.5%) | 28 (5.3%) | 0.089 |
| Oxygen inhalation, n (%) | 639 (78.9%) | 198 (70.2%) | 441 (83.5%) | <0.001 |
| Noninvasive ventilation, n (%)a | 76 (9.4%) | 13 (4.6%) | 63 (11.9%) | 0.001 |
| Invasive ventilation, n (%)a | 22 (2.7%) | 0 (0.0%) | 22 (4.2%) | 0.001 |
| Renal replacement therapy, n (%) | 15 (1.9%) | 5 (1.8%) | 10 (1.9%) | 1.000 |
| Extracorporeal membrane oxygenation, n (%)a | 4 (0.5%) | 0 (0.0%) | 4 (0.8%) | 0.304 |
a
Noninvasive ventilation, invasive ventilation, and extracorporeal membrane oxygenation are mutually exclusive
b
p values were calculated by Fisher's exact test or χ2 test